Novartis Doan's back pain relief superiority claims not supported, FTC judge concludes.
This article was originally published in The Tan Sheet
Executive Summary
NOVARTIS DOAN'S BACK PAIN RELIEF SUPERIORITY CLAIMS NOT SUPPORTED, FTC Administrative Law Judge Lewis Parker said in a March 9 decision and order upholding charges made by the Federal Trade Commission. Novartis is prohibited from claiming Doan's "is more effective than other over-the-counter analgesic drugs for relieving back pain or any other particular kind of pain, unless, at the time of making such representation, respondents possess and rely upon competent and reliable scientific evidence that substantiates the representation," the order states.